Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous UCD19 CAR T cells

A preparation of autologous peripheral blood lymphocytes (PBLs) that have been transduced with a lentiviral vector to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon transfusion, the autologous UCD19 CAR-T cells recognize and bind to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19, a B-cell-specific cell surface antigen is overexpressed in B-cell lineage malignancies.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous UCD19-CAR T lymphocytes

autologous UCD19 CAR T cells

Search NCI's Drug Dictionary